Medpace Hldgs: Q2 Earnings Insights

Shares of Medpace Hldgs MEDP moved higher by 15.7% in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 20.99% over the past year to $0.64, which beat the estimate of $0.40.

Revenue of $204,995,000 decreased by 4.25% year over year, which beat the estimate of $174,970,000.

Guidance

The upcoming fiscal year's EPS expected to be between $3.62 and $3.83.

The upcoming fiscal year's revenue expected to be between $880,000,000 and $920,000,000.

Price Action

Company's 52-week high was at $114.12

52-week low: $58.72

Price action over last quarter: Up 33.19%

Company Description

Medpace Holdings Inc is a clinical contract research organization. It is engaged in scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. It operates in North America, Europe, Africa, Middle East, Asia-Pacific and Latin America.